Supplementary Figure 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

• Alterations in gut microbiota may correlate with immune responses in CAR-T therapy for myeloma patients.
• Taxonomic profiles exhibit significant differences in relative abundances before and after lymphodepletion.
• The analysis focuses on apheresis umbilical microbiota to unveil taxonomic compositions affecting therapy outcomes.
• Findings highlight the necessity of considering microbiota profiles during CAR-T therapy in myeloma cases.